Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
10753 | 969 | 46.4 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | INTERLEUKIN 7 | Author keyword | 97 | 50% | 15% | 142 |
2 | IL 7 | Author keyword | 42 | 34% | 11% | 102 |
3 | INTERLEUKIN 7 RECEPTOR | Author keyword | 35 | 67% | 3% | 32 |
4 | IL 7 RECEPTOR | Author keyword | 14 | 55% | 2% | 17 |
5 | UNITE IMMUNOGENET CELLULAIRE | Address | 7 | 33% | 2% | 17 |
6 | CD127 | Author keyword | 6 | 30% | 2% | 18 |
7 | BIOL PROTECT | Address | 6 | 42% | 1% | 11 |
8 | SECT CYTOKINES IMMUN | Address | 5 | 60% | 1% | 6 |
9 | IL 7R | Author keyword | 5 | 40% | 1% | 10 |
10 | IL 7R ALPHA | Author keyword | 5 | 47% | 1% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | INTERLEUKIN 7 | 97 | 50% | 15% | 142 | Search INTERLEUKIN+7 | Search INTERLEUKIN+7 |
2 | IL 7 | 42 | 34% | 11% | 102 | Search IL+7 | Search IL+7 |
3 | INTERLEUKIN 7 RECEPTOR | 35 | 67% | 3% | 32 | Search INTERLEUKIN+7+RECEPTOR | Search INTERLEUKIN+7+RECEPTOR |
4 | IL 7 RECEPTOR | 14 | 55% | 2% | 17 | Search IL+7+RECEPTOR | Search IL+7+RECEPTOR |
5 | CD127 | 6 | 30% | 2% | 18 | Search CD127 | Search CD127 |
6 | IL 7R | 5 | 40% | 1% | 10 | Search IL+7R | Search IL+7R |
7 | IL 7R ALPHA | 5 | 47% | 1% | 8 | Search IL+7R+ALPHA | Search IL+7R+ALPHA |
8 | INTERLEUKIN 7 IL 7 | 4 | 56% | 1% | 5 | Search INTERLEUKIN+7+IL+7 | Search INTERLEUKIN+7+IL+7 |
9 | RS6897932 | 3 | 57% | 0% | 4 | Search RS6897932 | Search RS6897932 |
10 | IL 7 SIGNALING | 3 | 100% | 0% | 3 | Search IL+7+SIGNALING | Search IL+7+SIGNALING |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IL 7 | 146 | 48% | 23% | 221 |
2 | MURINE INTERLEUKIN 7 | 69 | 66% | 7% | 63 |
3 | INTERLEUKIN 7 | 53 | 29% | 16% | 157 |
4 | INTERLEUKIN 7 RECEPTOR | 49 | 27% | 16% | 154 |
5 | INTERLEUKIN 7 RECEPTOR EXPRESSION | 26 | 80% | 2% | 16 |
6 | IL 7R ALPHA EXPRESSION | 25 | 75% | 2% | 18 |
7 | IL 7 RECEPTOR | 20 | 30% | 6% | 55 |
8 | RECOMBINANT INTERLEUKIN 7 | 19 | 76% | 1% | 13 |
9 | HUMAN INTERLEUKIN 7 | 17 | 79% | 1% | 11 |
10 | CD127 EXPRESSION | 13 | 36% | 3% | 29 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Interleukin-7 receptor expression: intelligent design | 2007 | 242 | 114 | 46% |
Harnessing the biology of IL-7 for therapeutic application | 2011 | 117 | 128 | 38% |
Interleukin-7: from bench to clinic | 2002 | 260 | 178 | 55% |
The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance | 2005 | 285 | 70 | 41% |
Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy | 2015 | 1 | 79 | 56% |
Interleukin-7: Fuel for the autoimmune attack | 2013 | 13 | 124 | 47% |
IL-7 in human health and disease | 2012 | 26 | 83 | 41% |
Modulating T-cell homeostasis with IL-7: preclinical and clinical studies | 2009 | 47 | 110 | 65% |
The influence of HIV on CD127 expression and its potential implications for IL-7 therapy | 2012 | 12 | 125 | 62% |
IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis | 2012 | 28 | 104 | 28% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | UNITE IMMUNOGENET CELLULAIRE | 7 | 33% | 1.8% | 17 |
2 | BIOL PROTECT | 6 | 42% | 1.1% | 11 |
3 | SECT CYTOKINES IMMUN | 5 | 60% | 0.6% | 6 |
4 | BIOL PROTECTSAKYO KU | 3 | 60% | 0.3% | 3 |
5 | MONTREAL CHEST IMMUNODEFICIENCY SERV | 2 | 67% | 0.2% | 2 |
6 | REPROD ENGN TEAM | 2 | 43% | 0.3% | 3 |
7 | VIROIMMUNOL UNIT | 1 | 38% | 0.3% | 3 |
8 | CYTHERIS SA | 1 | 100% | 0.2% | 2 |
9 | TECHNOPOLIS | 1 | 50% | 0.2% | 2 |
10 | EVANS CLIN | 1 | 20% | 0.4% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000209634 | EXPTL IMMUNOL UNIT//BN 52080//GLUCOCORTICOIDS SYNTHETIC |
2 | 0.0000145573 | THYMIC STROMAL LYMPHOPOIETIN//TSLP//THYMIC STROMAL LYMPHOPOIETIN TSLP |
3 | 0.0000135747 | IMMUNE RECONSTITUTION//CLIN MOL RETROVIROL SECT//IMMUNE ACTIVATION |
4 | 0.0000133284 | PAX5//EXPT HEMATOPOIESIS UNIT//EBF |
5 | 0.0000132465 | INTERDISCIPLINARY PROGRAM IMMUNOL//INTEGRATED IMMUNOL VACCINE//T CELL COMPETITION |
6 | 0.0000120206 | INTERLEUKIN 15//IL 15//IL 15R ALPHA |
7 | 0.0000105640 | TOFACITINIB//JAK3//CP 690 550 |
8 | 0.0000086626 | T CELL DEVELOPMENT//PRE T CELL RECEPTOR//THYMIC SELECTION |
9 | 0.0000080731 | OMENN SYNDROME//SEVERE COMBINED IMMUNODEFICIENCY//T CELL LYMPHOPENIA |
10 | 0.0000061163 | LYMPHOCYTE RECOVERY//IMMUNE RECONSTITUTION//BMT RECIPIENTS |